VarmX
Business Services · Netherlands · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Emmy Noetherweg 2, Leiden, South Holland...Phone Number
+31 715156127Website
www.varmx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About VarmX
VarmX is a biotechnology company developing therapies to restore blood coagulation in patients using Factor Xa direct oral anticoagulants. Its lead program focuses on treating severe bleeding and reducing surgical bleeding risk through a universal bypassing agent designed to rapidly support hemostatic control.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is VarmX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if VarmX has recently received funding, and reach out quickly before it becomes old news!
Click to see if VarmX had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at VarmX
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once VarmX has new funding data
Check out if VarmX is spiking on competitors!
Earning: See what the market has to say on VarmX recently announced quarterly report
VarmX, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when VarmX launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
VarmX is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
VarmX is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about VarmX.
VarmX financials insights
Gather financial insights about VarmX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$9M
2023
Series B
$68.2M
VarmX Tech Stack
A closer look at the technologies used by VarmX
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves, Board of Directors
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
New Hire
Executive Move
Executive Moves, New Hire
VarmX News & Media
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001
Drug developer VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001, enabling it to go straight to Phase 3 studies in Japan.CSL nabs option to acquire a startup and its blood-clotting drug | BioPharma Dive
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding.Australia's CSL invests $117 million for VarmX acquisition option, coagulation treatment
(Reuters) -Australia's CSL said on Tuesday it will pay $117 million upfront to Dutch firm VarmX for an exclusive option to acquire the privately held company and advance the development of a blood coagulation treatment. The deal gives CSL the right to ...VarmX Announces Appointment of John Glasspool as CEO
LEIDEN, Netherlands--(BUSINESS WIRE)--VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed international life sciences industry veteran John Glasspool as CEO, with immediate effect. John joins VarmX from the position of CEO at Anthos Therapeutics, a clinical-stage biopharmaceutical company developing therapies for high-risk cardiovascular patients, inclu
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding VarmX
Sign Up For FreeTo access detailed company insights
VarmX is a biotechnology company developing therapies to restore blood coagulation in patients using Factor Xa direct oral anticoagulants. Its lead program focuses on treating severe bleeding and reducing surgical bleeding risk through a universal bypassing agent designed to rapidly support hemostatic control.... Read More
